Insulet (NASDAQ:PODD) Price Target Raised to $310.00

Insulet (NASDAQ:PODD) had its price objective increased by Citigroup from $283.00 to $310.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

A number of other equities analysts have also commented on PODD. Barclays boosted their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. BTIG Research upped their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Piper Sandler raised their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Raymond James upped their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Finally, Morgan Stanley raised their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $267.44.

Insulet Price Performance

Shares of PODD stock opened at $269.34 on Wednesday. The firm has a market cap of $18.89 billion, a price-to-earnings ratio of 46.12, a P/E/G ratio of 4.18 and a beta of 1.21. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock’s fifty day simple moving average is $251.37 and its 200 day simple moving average is $220.02. Insulet has a one year low of $160.19 and a one year high of $279.77.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PODD. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC acquired a new stake in Insulet during the 2nd quarter worth $32,000. Venturi Wealth Management LLC raised its stake in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. lifted its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new position in Insulet in the second quarter valued at about $52,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.